参芪扶正注射液联合希罗达在晚期乳腺癌维持治疗中的疗效观察

目的 探讨参芪扶正注射液联合希罗达治疗复发转移乳腺癌的近期疗效和不良反应.方法 40例复发转移性乳腺癌患者,并已进行6～8周期一线治疗,根据治疗方法不同分为实验组与对照组.实验组20例,给予参芪扶正注射液250ml,静脉滴注,1次/天,连用14天＋希罗达800～1000mg/（m2·d）分2次口服,对照组20例,单药希罗达800～1000mg/（m2· d）分2次口服.结果 总有效率两组比较有显著差异性（P＜0.05）.两组治疗前后白细胞变化、胃肠道反应率、卡氏评分改善率比较有显著性差异（P＜0.01）治疗组生活质量较对照组明显改善.结论 参芪扶正注射液联合希罗达治疗复发转移性乳腺癌可减轻化疗引起的毒副作用,使患者化疗依从性更好,从而提高机体免疫功能.

The observation of SFI combined with capecitabineon in the maintenance Treatment of metastatic breast cancer

Objective To evaluate the responserate and advesre reaction of Capecitabine in the Maintenance treatment Of meta- static breast cancer（MBC）. Methods Forty patients who have been carried out 6 to8 cycles of first--line treatment were divided into experimental group and control group according to the different treatment methods. With in the experimental group （n = 20）were given SFI 250ml ivdrip qd for two weeks combined with Capeeitabine 800 - 10OOmg/m2, bid, with sustained drug delivery. With in the control group （ n = 20 ） , Capecitabine 800 - 1000mg/m2, bid with sustained drug delivery. Results The totale efficiency of the two groups was significantly diferent（ P 〈 O. 05 ）. Changes in white blood cells before and after treatment, there was significant differ- ent Qualiyt of life in the treatment group improved signiifcantly than the control group. Conclusion SFI combined with Capecitabine Can reduce chemotherapy--induced side effects in the Maintenance treatment Of metastatic breast cancer（MBC） , better complinaee to chemotherapy, enhance immue function.